Phesgo 600/600 mg and 1 200/600 mg Subcutaneous injection
PDF Leaflet Revision Date: 20 June 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HER2-positive breast cancer.
Dosage (summary)
Loading dose: 1200 mg/600 mg SC, Maintenance: 600 mg/600 mg SC every 3 weeks.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Avoid during pregnancy; may cause fetal harm. Discontinue breastfeeding during treatment and for 7 months after.
Key Drug Interactions
- Docetaxel
- Anthracyclines
Contraindications
- Hypersensitivity to pertuzumab or trastuzumab
Common side effects
- Injection site reactions
- Fatigue
- Anemia
- Dyspnea
Counselling Points
- Monitor for injection-related reactions
- Use effective contraception during treatment
- Report any signs of heart failure.
Serious warnings
- Cardiomyopathy
- Embryo-fetal toxicity
- Pulmonary toxicity
Important Disclaimer
The Phesgo 600/600 mg and 1 200/600 mg Subcutaneous injection professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
